On Monday (November 6th) Eastern Time, Dr. Daniel Skovoronsky, the chief scientist of Eli Lilly (NYSE: LLC, stock price $595.19, market value $565 billion), the world's highest pharmaceutical company ...

Dr. Daniel Skovronsky, Chief Scientific Officer of Lilly, the world's most valuable pharmaceutical company, stated with extreme optimism that a major breakthrough in the treatment of Alzheimer's dise ...

On November 20th, The Information reported, citing two sources familiar with the matter, that if dismissed CEO Sam Altman returns to his position, Microsoft will consider taking a seat on the OpenAI ...

According to Reuters on the 20th, Microsoft CEO Nadella announced on social media that former CEO Sam Altman and former CEO Greg Brockman of the American artificial intelligence research company Open ...

According to a report by the Wall Street Journal on the 20th, hopes of Sam Atlman, former CEO of artificial intelligence startup OpenAI, returning to his position have been shattered. On the other ha ...

He is the soul of OpenAI, a genius and a madman. If he leaves, this AI company may lose its soul, lose its temperature, and passion. In the eyes of Feng Li, a doctoral supervisor at the School of Com ...

Lilly Pharmaceuticals announced on March 8th local time that the US Food and Drug Administration (FDA) has notified the company to further understand and evaluate the safety and efficacy of its new A ...

On April 6th local time, according to technology media The Information, Sam Altman, CEO of OpenAI, and former Apple design director Johnny Avi, a startup founded by OpenAI, announced new financing ne ...

On June 10th, Lilly's Alzheimer's disease (AD) drug Donanemab was unanimously approved by the FDA's Advisory Committee on Peripheral and Central Nervous System Drugs (PCNS).

Lilly's new drug for Alzheimer's disease, Kisunla, has been approved by the US FDA. On July 2nd, Lilly announced that the US Food and Drug Administration (FDA) has approved Kisunla for the treatment ...

After more than half a year of delay from the initial expected approval time, Lilly's Alzheimer's disease treatment drugs have finally been approved in the United States. On July 2nd local time, Eli ...

On November 13th, the Central Social Insurance Medical Agreement, a consulting agency of the Japanese Ministry of Health, Labour and Welfare, approved the official pricing of the new Alzheimer's dise ...

On December 18th, Eli Lilly announced that its Alzheimer's disease therapy, Genentech&Co., Ltd; reg; Duonai monoclonal antibody injection has been registered and approved by the National Medical Prod ...

Beijing News On December 18, Lilly's official WeChat official account announced that its Alzheimer's disease treatment Donetumab injection (trade name: Minonda®, Intravenous infusion once every f ...

On December 18th, the National Medical Products Administration of China approved Eli Lilly and Company's (hereinafter referred to as "Eli Lilly") Alzheimer's disease therapy, JiNengda&Co; reg; (Donai ...